A few prospective studies have suggested that AI use in mammography screening increases cancer detection. However, cancer detection supported with AI should not predominately identify indolent cancers or occur at the expense of more false positives; instead, AI usage should increase the detection of clinically relevant cancers.
About the study
In the present study, researchers assessed the performance of cancer screening measures in the MASAI trial. The trial was designed to compare AI-supported mammography screening with standard double-reading.
Revolutionizing the fight against brain cancers — dr. thomas chen MD, phd, FAANS, — CEO/CSO, neonc technologies holdings inc.
Dr. Thomas Chen, MD, Ph.D. is Founder, CEO & CSO, and Board Director, of NeOnc Technologies (https://neonc.com/), a developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB), providing patients with potentially more effective treatments.
NeOnc is developing a portfolio of treatments for brain cancer and other central nervous system (CNS) disorders.
Dr. Chen is a board-certified neurosurgeon and the Director of Surgical Neuro-Oncology at USC where he is also a tenured Professor of Neurosurgery and Pathology (https://keck.usc.edu/faculty-search/thomas-c-chen/).
Dr. Chen graduated summa cum laude from the University of Illinois at Urbana-Champaign, where he also received Bronze Tablet honors and was inducted into the Phi Beta Kappa national academic honor society. He attended the University of California, San Francisco, where he obtained his MD, and was inducted into the Alpha Omega Alpha National Medical Honor Society. He underwent neurosurgery training at USC and obtained a Ph.D. degree in pathobiology where his thesis was on the role of immunotherapy in malignant brain tumors.
Researchers are studying whether the drugs that upended diabetes and obesity care could also revolutionise Alzheimer’s treatment. Here’s what they have learnt so far.
Olive oil bioactives, including MUFAs, polyphenols, and triterpenoids, modulate gene expression linked to insulin sensitivity, inflammation, and beta-cell function, offering potential benefits for Type 2 Diabetes Mellitus prevention and management.
The rise of antimicrobial resistance has rendered many treatments ineffective, posing serious public health challenges. Intracellular infections are particularly difficult to treat since conventional antibiotics fail to neutralize pathogens hidden within human cells. However, designing molecules that penetrate human cells while retaining antimicrobial activity has historically been a major challenge. Here, we introduce APEXDUO, a multimodal artificial intelligence (AI) model for generating peptides with both cell-penetrating and antimicrobial properties. From a library of 50 million AI-generated compounds, we selected and characterized several candidates. Our lead, Turingcin, penetrated mammalian cells and eradicated intracellular Staphylococcus aureus. In mouse models of skin abscess and peritonitis, Turingcin reduced bacterial loads by up to two orders of magnitude. In sum, APEXDUO generated multimodal antibiotics, opening new avenues for molecular design.
CFN provides consulting services to Invaio Sciences and is a member of the Scientific Advisory Boards of Nowture S.L., Peptidus, European Biotech Venture Builder and Phare Bio. CFN is also a member of the Advisory Board for the Peptide Drug Hunting Consortium (PDHC). The de la Fuente Lab has received research funding or in-kind donations from United Therapeutics, Strata Manufacturing PJSC, and Procter & Gamble, none of which were used in support of this work. An invention disclosure associated with this work has been filed. All other authors declare no competing interests.
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.
The vaccines were administered after surgery to remove the tumor and are designed to train the body’s immune system to recognize and eliminate any remaining tumor cells. At the time of data cut-off (median of 34.7 months), all patients remained cancer-free.
The results of this Phase I trial were reported in Nature.
The motivation behind the new study was to address these gaps in our understanding by leveraging the power of large-scale data. The researchers recognized that investigating the connection between genetic predisposition to dyslexia and brain structure in a very large sample could provide more robust and reliable insights than smaller, more traditional studies. They aimed to identify specific brain regions and white matter tracts that are associated with genetic risk for dyslexia, and to explore whether different genetic variants might influence distinct neural pathways.
“Thirty-five genetic variants that influence the chance of having dyslexia were already known from a very large study by the company 23andMe in the USA, carried out in over one million people. However, that study did not include brain MRI data. The new aspect of our study was to investigate the genetic variants in relation to brain structure in MRI data from thousands of people,” explained Clyde Francks (@clydefrancks), a professor at the Max Planck Institute for Psycholinguistics in Nijmegen and senior author of the study.
The researchers used two large datasets: the genetic data 23andMe and brain imaging data from over 30,000 adults in the UK Biobank. The 23andMe dataset helped identify genetic variants associated with dyslexia by comparing individuals who reported a dyslexia diagnosis to those who did not. These genetic variants were then used to calculate “polygenic scores” for individuals in the UK Biobank, reflecting their genetic predisposition to dyslexia.
DNA-nanoparticle motors are exactly as they sound: tiny artificial motors that use the structures of DNA and RNA to propel motion through enzymatic RNA degradation. Essentially, chemical energy is converted into mechanical motion by biasing the Brownian motion.
The DNA-nanoparticle motor uses the “burnt-bridge” Brownian ratchet mechanism. In this type of movement, the motor is propelled by the degradation (or “burning”) of the bonds (or “bridges”) it crosses along the substrate, essentially biasing its motion forward.
These nano-sized motors are highly programmable and can be designed for use in molecular computation, diagnostics, and transport.
Tags; #science #neuroscience #happiness #happiness #neurodegenerativediseases #disease #health #mentalhealth #sleep #neuroscientist #disease #education #success. ****************** About me: I am Shambhu Yadav, Ph.D., a research scientist at Harvard Medical School (Boston, MA, USA). I also work (for fun) as a Science Journalist, editor, and presenter on a YouTube channel. Science Communication is my passion.
*********************************************************** Disclaimer 1: The video content is for educational and informational purposes only, not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider regarding any medical condition. Do not disregard or delay seeking professional medical advice based on information from this video. Any reliance on the information provided is at your own risk. Disclaimer 2: The Diary Of A Scientist (DOAS) channel does not promote or encourage any unusual activities, and all content provided by this channel is meant for EDUCATIONAL purposes only.
*Credits and thanks** The video was recorded using iPhone and edited using Adobe Premiere Pro: a timeline-based and non-linear video editing software. Music source: Epidemic sound.
